Goldman Sachs Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $38

Benzinga · 2d ago
Goldman Sachs analyst Richard Law maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and raises the price target from $26 to $38.